Radionuclide by-products characterization of a 2 hours 100µA 16MeV proton beam irradiation use for 18F- production with a single [18O]-H2O target
Guillaume Andreolety; Justin Panarin; Nick Walter; Gilles Triscone; Tomas Eriksson
Advanced Accelerator Applications a Novartis company; HEPIA HES-SO University of Applied Sciences; GEMS PET Systems AB
Oral Presentation
I declare to have no conflict of interest
18F- radio-isotopes is widely used in radiopharmacy notably for [18F-]FDG. Its production is done with nuclear interaction of a protons beam at high energy with 18O enriched water. The resulting 18O(p,n)18F reaction is mainly promoted but some by-products are generated from competitive reactions with target interaction components. These species are successfully removed in the synthesis process at the expense of radioactive waste stream. Identification and quantifications of these radionuclides is a radioprotection question to evaluate handling and storage of the waste. This study focuses on the by-products obtained with the last target design 18F- Nb27 self-shielded developed by GE Healthcare for the PETtrace 880 cyclotron at high current (100 μA) to reflect the future production standard. Measurements were performed with HPGe gamma spectrometer and with Liquid Scintillation Counter through a pyrolysis process. The results shown a presence of species coming from the Havar® foil with 55-58Co, 95Tc and 181-182Re to cite the most abundant elements. Tritium, generated with 18O(p,t)16O reaction, is found in quantity proportional to the applied beam current. This study at 100 μA single beam brings key information both for worker protection guideline and radioactive waste management.
I did not detect anything new other than the quantities of the side products from foil recoils. Therefore I would recommend a poster for this paper.
I agree but still interesting as a reminder for production pharmacists !